Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on ...
Without the right oxygen balance, phosphorus and nitrogen vanish — and life can't take hold. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.
The GALARISSO DM study met its primary endpoint, showing that GLPG3667, administered once daily at 150 mg (N=21) in addition to standard-of-care therapy, achieved a statistically significant clinical ...
Galapagos will evaluate all strategic alternatives, including resumption of its partnering process, to accelerate further development of GLPG3667 in dermatomyositis and potentially other severe ...
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to ...
Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China ...
Ladies and gentlemen, thank you for standing by. Welcome to VALOR Phase III study results [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results